ES2112865T3 - Anticuerpos igg purificados. - Google Patents

Anticuerpos igg purificados.

Info

Publication number
ES2112865T3
ES2112865T3 ES91917891T ES91917891T ES2112865T3 ES 2112865 T3 ES2112865 T3 ES 2112865T3 ES 91917891 T ES91917891 T ES 91917891T ES 91917891 T ES91917891 T ES 91917891T ES 2112865 T3 ES2112865 T3 ES 2112865T3
Authority
ES
Spain
Prior art keywords
antibody
column
applying
absorb
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91917891T
Other languages
English (en)
Other versions
ES2112865T5 (es
Inventor
Paul Ian Nicholas Ramage
Geoffrey Langley Court Allen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10683866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2112865(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of ES2112865T3 publication Critical patent/ES2112865T3/es
Application granted granted Critical
Publication of ES2112865T5 publication Critical patent/ES2112865T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un procedimiento para obtener una preparación purificada de un anticuerpo IgG anti-CDW 52 preparado utilizando un sistema de expresión recombinante, comprendiendo dicho procedimiento: (a) aplicar una solución acuosa del anticuerpo a una columna de Proteína A o Proteína G para absorber el anticuerpo en la columna y después eluir el anticuerpo con una solución ácida de un pH desde 3,0 hasta 3,5; (b) aplicar el eluído ácido a una columna de intercambio iónico de partículas cargadas para absorber el anticuerpo en la columna y después eluir el anticuerpo con una solución ácida de iones con carga contraria; y (c) aplicar el eluído acuoso a una columna de exclusión molecular de partículas porosas para retener las moléculas no-anticuerpo en las partículas porosas y para obtener el anticuerpo deseado en fracciones seleccionadas eluídas de la columna que contienen menos del 2% de agregado de anticuerpo según se midió por cromatografía de exclusión según tamaño.
ES91917891T 1990-10-17 1991-10-17 Anticuerpos igg purificados. Expired - Lifetime ES2112865T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9022547 1990-10-17
GB909022547A GB9022547D0 (en) 1990-10-17 1990-10-17 Purified immunoglobulin

Publications (2)

Publication Number Publication Date
ES2112865T3 true ES2112865T3 (es) 1998-04-16
ES2112865T5 ES2112865T5 (es) 2007-09-16

Family

ID=10683866

Family Applications (2)

Application Number Title Priority Date Filing Date
ES09250029A Expired - Lifetime ES2081742B1 (es) 1990-10-17 1991-10-17 Procedimiento para preparar inmunoglobulina purificada.
ES91917891T Expired - Lifetime ES2112865T5 (es) 1990-10-17 1991-10-17 Anticuerpos igg purificados.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES09250029A Expired - Lifetime ES2081742B1 (es) 1990-10-17 1991-10-17 Procedimiento para preparar inmunoglobulina purificada.

Country Status (29)

Country Link
US (1) US5644036A (es)
EP (1) EP0504363B2 (es)
JP (1) JP2638680B2 (es)
KR (2) KR960015399B1 (es)
AT (2) ATE162552T1 (es)
AU (3) AU658926B2 (es)
BE (1) BE1004226A5 (es)
BR (1) BR1100358A (es)
CA (1) CA2069481C (es)
CH (2) CH681305A5 (es)
DE (1) DE69128774T3 (es)
DK (1) DK0504363T4 (es)
ES (2) ES2081742B1 (es)
FI (2) FI110003B (es)
FR (2) FR2668164A1 (es)
GB (2) GB9022547D0 (es)
GR (3) GR910100425A (es)
HU (1) HUT64601A (es)
IE (1) IE913560A1 (es)
IL (3) IL102726A (es)
IT (1) IT1250064B (es)
LU (1) LU88122A1 (es)
MX (1) MX9203794A (es)
MY (2) MY119030A (es)
NZ (2) NZ244114A (es)
PT (2) PT99248B (es)
TW (1) TW283710B (es)
WO (1) WO1992007084A1 (es)
ZA (2) ZA918259B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
KR100264218B1 (ko) * 1991-10-15 2000-08-16 그레이엄 브레레톤 관절의 T-세포 매개 염증의 치료용 CDw52-특이 항체
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
GB9300501D0 (en) * 1993-01-09 1993-03-03 Wellcome Found Purification of immunoglobulin
WO1997004803A1 (fr) † 1995-08-01 1997-02-13 Pasteur Merieux Serums & Vaccins Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
GB9603256D0 (en) * 1996-02-16 1996-04-17 Wellcome Found Antibodies
US20030023043A1 (en) * 2000-03-02 2003-01-30 Kazuhisa Uchida Method of separating and purifying protein
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
EP1404428B1 (en) * 2001-06-05 2006-07-19 Genetics Institute, LLC Methods for purifying highly anionic proteins
GB0220894D0 (en) * 2002-09-09 2002-10-16 Millipore Uk Ltd Method of separation
CN100522989C (zh) 2002-09-11 2009-08-05 中外制药株式会社 纯化蛋白质的方法
JP5116971B2 (ja) 2002-10-15 2013-01-09 インターセル アーゲー Ｂ群連鎖球菌の接着因子をコードする核酸、ｂ群連鎖球菌の接着因子、およびその使用
GB0304576D0 (en) * 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
WO2005062893A2 (en) * 2003-12-22 2005-07-14 Genzyme Corporation Anti-cd52 antibody treatment for diabetes
BRPI0608584B8 (pt) * 2005-03-11 2021-05-25 Wyeth Corp métodos de recuperar um produto purificado
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
BRPI1013927A2 (pt) 2009-05-13 2016-04-05 Genzyme Corp métodos e composições para o tratamento de lúpus
MX2011012047A (es) 2009-05-13 2011-12-14 Genzyme Corp Inmunoglobulinas humanas anti-cd52.
WO2011090719A2 (en) * 2009-12-29 2011-07-28 Dr. Reddy's Laboratories Ltd. Protein purification by ion exchange
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
RU2467783C2 (ru) * 2010-07-30 2012-11-27 Закрытое акционерное общество "БиоХимМак СТ" Способ хроматографического выделения иммуноглобулина
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9650411B2 (en) 2012-08-07 2017-05-16 Kyowa Hakko Kirin Co., Ltd. Method of purifying protein
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10654933B2 (en) 2013-12-27 2020-05-19 Chugai Seiyaku Kabushiki Kaisha Method for purifying antibody having low isoelectric point
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3330279B1 (en) 2015-07-31 2022-04-06 Chugai Seiyaku Kabushiki Kaisha Method for purifying composition comprising antibodies with anionic polymer
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
WO2018022628A1 (en) 2016-07-25 2018-02-01 Cephalon, Inc. Affinity chromatography wash buffer
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN113646066B (zh) 2019-03-29 2024-05-31 旭化成医疗株式会社 蛋白质的纯化方法
US12383884B2 (en) 2019-04-08 2025-08-12 Asahi Kasei Medical Co., Ltd. Polyamide medium for purifying protein-containing solution and method for producing polyamide medium
BR112021020204A2 (pt) 2019-04-10 2021-12-07 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo com região fc modificada
WO2022260091A1 (ja) 2021-06-10 2022-12-15 三菱ケミカル株式会社 合成吸着剤、抗体の精製方法及び抗体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) * 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
CA1339198C (en) * 1988-02-12 1997-08-05 Gregory Paul Winter Antibodies to the antigen campath-1

Also Published As

Publication number Publication date
FI922824L (fi) 1992-06-17
ES2081742A1 (es) 1996-03-01
AU2532192A (en) 1993-02-11
FR2677997A1 (fr) 1992-12-24
IL102726A (en) 2002-08-14
AU8729491A (en) 1992-05-20
WO1992007084A1 (en) 1992-04-30
MY136210A (en) 2008-08-29
HUT64601A (en) 1994-01-28
DK0504363T4 (da) 2007-05-29
PT100988B (pt) 1999-08-31
CA2069481C (en) 2003-07-29
JP2638680B2 (ja) 1997-08-06
PT99248A (pt) 1993-06-30
MX9203794A (es) 1992-07-01
FI110002B (fi) 2002-11-15
ITRM910788A0 (it) 1991-10-16
GR920100471A (el) 1994-06-30
CH681305A5 (es) 1993-02-26
TW283710B (es) 1996-08-21
IE913560A1 (en) 1992-04-22
FR2668164B1 (es) 1995-04-14
EP0504363B1 (en) 1998-01-21
FI922380L (fi) 1992-05-25
DE69128774T3 (de) 2007-08-16
GR910100425A (el) 1992-09-25
KR100193314B1 (ko) 1999-06-15
AU658926B2 (en) 1995-05-04
GB9022547D0 (en) 1990-11-28
LU88122A1 (fr) 1993-03-15
ATE162552T1 (de) 1998-02-15
IL102726A0 (en) 1993-01-31
AU649078B2 (en) 1994-05-12
NZ240247A (en) 1994-03-25
ATA900791A (de) 1996-06-15
KR960015399B1 (ko) 1996-11-13
DE69128774T2 (de) 1998-06-04
IT1250064B (it) 1995-03-30
FI922380A0 (fi) 1992-05-25
NZ244114A (en) 1995-06-27
AU7024294A (en) 1995-01-05
ZA926191B (en) 1993-04-16
CH681455A5 (es) 1993-03-31
KR920703108A (ko) 1992-12-17
CA2069481A1 (en) 1992-04-18
PT99248B (pt) 1999-04-30
US5644036A (en) 1997-07-01
AU4521897A (en) 1998-02-12
GB9209529D0 (en) 1992-07-01
ITRM910788A1 (it) 1993-04-16
ES2081742B1 (es) 1996-10-01
AU716402B2 (en) 2000-02-24
BR1100358A (pt) 2000-03-28
ZA918259B (en) 1993-04-16
DK0504363T3 (da) 1998-09-21
JPH05504579A (ja) 1993-07-15
EP0504363B2 (en) 2007-02-07
FI922824A0 (fi) 1992-06-17
GR3026588T3 (en) 1998-07-31
FR2668164A1 (fr) 1992-04-24
HU9202000D0 (en) 1992-10-28
ES2112865T5 (es) 2007-09-16
FI110003B (fi) 2002-11-15
BE1004226A5 (fr) 1992-10-13
MY119030A (en) 2005-03-31
EP0504363A1 (en) 1992-09-23
GB2253397A (en) 1992-09-09
DE69128774D1 (de) 1998-02-26
PT100988A (pt) 1994-02-28
IL99761A0 (en) 1992-08-18

Similar Documents

Publication Publication Date Title
ES2081742A1 (es) Procedimiento para preparar inmunoglobulina purificada.
ES2106742T3 (es) Procedimiento de purificacion de proteinas.
EP0173648A3 (en) New monoclonal antibodies to glycoconjugates, processes for their production, and applications
ATE124703T1 (de) Verfahren zur trennung von proteinen.
FR2487642B2 (fr) Procede de preparation de fractions proteiques par ultrafiltration et chromatographie d'exclusion et d'echange d'ions
EP0087686A3 (en) Homogeneous human immune interferon and process therefor
GB1213445A (en) Plate for thin layer chromatography
IT1257908B (it) Proccedimento per la produzione di ittrio-90 e generatore di ittrio-90
Cooke et al. The chromatography of serum proteins on cellulose ion exchange columns
FI952140A0 (fi) Menetelmä radioaktiivisella jodilla leimatun TSH-merkin tuottamiseksi ja sen käyttö merkkinä TSH-reseptorimäärityksessä
RU2087151C1 (ru) Способ получения высокочистого инсулина
ES321509A1 (es) Procedimiento para fabricar gonadotropinas muy purificadas mediante cromatografia.
Faye et al. Systematic use of affinity difference between immobilized lectin gels for demonstration of glycoprotein molecular variants: The example of radish β-fructosidase
Nomura et al. The structure of tobacco mosaic virus from base analogue treated tobacco leaves
DE4002044A1 (de) Thiophile adsorbentien
DENG PURIFICATION OF HUMAN INTERFERON-? BY ANTIBODY AFFINITY CHROMATOGRAPY

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 504363

Country of ref document: ES